Insider Trades17 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | Buy | ZYME | Mark Hollywood | EVP & Chief Operating Officer | 939 | $22.22 | $2.0B | -16.27% | +76.34% | $20.9K | +0.71% | — | Sell Now |
| Jan 12, 2026 | Sell | ZYME | Mark Hollywood | EVP & Chief Operating Officer | 6,120 | $22.67 | $2.0B | -16.27% | +76.34% | $138.8K | -1.71% | — | Sell Now |
| Jan 12, 2026 | Sell | ZYME | Jeffrey T L Smith | EVP & Chief Medical Officer | 9,310 | $22.67 | $2.0B | -16.27% | +76.34% | $211.1K | -13.05% | — | Sell Now |
| Jan 12, 2026 | Sell | ZYME | Paul Andrew Moore | Chief Scientific Officer | 9,560 | $22.67 | $2.0B | -16.27% | +76.34% | $216.8K | -3.46% | — | Sell Now |
| Jan 12, 2026 | Sell | ZYME | Kenneth Galbraith | Chair & CEO | 30,424 | $22.67 | $2.0B | -16.27% | +76.34% | $689.8K | -3.15% | — | Sell Now |
| Jan 6, 2026 | Buy | ZYME | Leone D Patterson | EVP, Chief Bus & Fin Officer | 459 | $10.55 | $2.0B | -16.27% | +76.34% | $4.8K | — | — | Sell Now |
| Jan 5, 2026 | Sell | ZYME | Jeffrey T L Smith | EVP & Chief Medical Officer | 10,538 | $25.10 | $2.0B | -16.27% | +76.34% | $264.5K | -21.55% | — | Sell Now |
| Jan 5, 2026 | Sell | ZYME | Paul Andrew Moore | Chief Scientific Officer | 20,110 | $25.10 | $2.0B | -16.27% | +76.34% | $504.7K | -18.00% | — | Sell Now |
| Jan 5, 2026 | Sell | ZYME | Kenneth Galbraith | Chair & CEO | 54,343 | $25.10 | $2.0B | -16.27% | +76.34% | $1.4M | -11.50% | — | Sell Now |
| Dec 22, 2025 | Sell | ZYME | Kenneth Galbraith | Chair & CEO | 47,528 | $27.02 | $2.0B | -16.27% | +76.34% | $1.3M | -26.29% | — | Sell Now |
| Jan 6, 2025 | Sell | ZYME | Jeffrey T L Smith | EVP & Chief Medical Officer | 11,110 | $14.92 | $2.0B | -16.27% | +76.34% | $165.8K | -18.52% | — | Sell Now |
| Jan 6, 2025 | Sell | ZYME | Paul Andrew Moore | Chief Scientific Officer | 21,200 | $14.92 | $2.0B | -16.27% | +76.34% | $316.4K | -18.21% | — | Sell Now |
| Jan 6, 2025 | Sell | ZYME | Kenneth Galbraith | Chair & CEO | 57,291 | $14.92 | $2.0B | -16.27% | +76.34% | $855.0K | -15.63% | — | Sell Now |
| Jan 5, 2024 | Sell | ZYME | Christopher Astle | SVP & Chief Financial Officer | 5,994 | $10.79 | $2.0B | -16.27% | +76.34% | $64.7K | -4.94% | — | Sell Now |
| Jan 5, 2024 | Sell | ZYME | Paul Andrew Moore | Chief Scientific Officer | 9,799 | $10.79 | $2.0B | -16.27% | +76.34% | $105.7K | -4.64% | — | Sell Now |
| Jan 5, 2024 | Sell | ZYME | Kenneth Galbraith | Chair & CEO | 23,904 | $10.79 | $2.0B | -16.27% | +76.34% | $257.8K | -3.55% | — | Sell Now |
| Dec 11, 2023 | Sell | ZYME | Christopher Astle | SVP & Chief Financial Officer | 886 | $9.13 | $2.0B | -16.27% | +76.34% | $8.1K | -30.73% | — | Sell Now |